3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Myeloid
2
Conditions
Myelodysplastic Syndromes
2
Leukemia, Myeloid, Acute
2
Urinary Tract Infections
1
Urinary Bladder Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neutropenia
1
Myeloproliferative Disorders
1
Febrile Neutropenia
1
Interventions
fludarabine
52
Cyclophosphamide
50
venetoclax
47
Azacitidine
44
fludarabine phosphate
41
Whole-Body Irradiation
33
Specimen Handling
31
Mycophenolic Acid
30
Tacrolimus
28
Melphalan
28
Busulfan
27
Cytarabine
25
Stem Cell Transplantation
23
Decitabine
23
Biopsy
22
Granulocyte Colony-Stimulating Factor
19
Sirolimus
16
Peripheral Blood Stem Cell Transplantation
16
Filgrastim
16
Thiotepa
15
decitabine and cedazuridine drug combination
14
Injections
13
Cyclosporine
13
ruxolitinib
9
Methotrexate
9
Mesna
9
Hematopoietic Stem Cell Transplantation
9
X-Rays
8
Idarubicin
8
Daunorubicin
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Myelodysplastic Syndromes
×
Levofloxacin
×
1 year
×
Clear all
NCT07528417
2026-04-22
MYELO-CAN:ABX
University of Manitoba
Phase 2
Not yet recruiting
75 enrolled
NCT03594149
2026-01-02
AZABAC
Centre Henri Becquerel
Phase 3
Completed
60 enrolled